"Intrathecal Delivery of Riluzole: A Clear Efficacy in ALS Therapy"
Brain Trust Bio has been approved to conduct Phase 1 clinical trials in Australia to test the efficacy of its intrathecal delivery method for ALS therapy riluzole, which aims to enhance therapeutic benefits while minimizing side effects. The approach involves directly infusing medication into the spinal canal to bypass the blood brain barrier and access the central nervous system. Early signs suggest that this method may be more effective than existing delivery modes, potentially extending survival by a year or more. The company also plans to evaluate its delivery method in multiple sclerosis and spinal cord cancer.